UCB (OTCMKTS:UCBJF) Shares Gap Up – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares gapped up before the market opened on Friday . The stock had previously closed at $284.2414, but opened at $297.4480. UCB shares last traded at $297.4480, with a volume of 135 shares.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on UCBJF shares. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a report on Monday, February 16th. Wolfe Research initiated coverage on UCB in a report on Monday, February 23rd. They issued an “outperform” rating on the stock. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy”.

UCB Stock Performance

The firm has a fifty day simple moving average of $294.62 and a two-hundred day simple moving average of $297.44. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.